CORT108297 for Alzheimer's Disease
(CORT-X Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment called CORT108297 to determine its potential in reducing stress-related brain damage in people with Alzheimer’s disease. Researchers aim to assess whether this drug can improve memory and thinking skills in individuals with mild cognitive impairment due to Alzheimer's or those at risk due to family history or other factors. Participants will receive both the actual drug and a placebo (inactive treatment) to compare results. This study may suit individuals with mild memory issues linked to Alzheimer's or those concerned about developing Alzheimer's due to family history, provided they are in good overall health. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.
Will I have to stop taking my current medications?
The trial requires that you have not been treated with certain medications like antidepressants, neuroleptics, sedative hypnotics, or glucocorticoids in the last six months. Also, you cannot use medications metabolized by specific enzymes or CYP3A inhibitors during the trial. Exceptions may be considered by the study leader.
Is there any evidence suggesting that CORT108297 is likely to be safe for humans?
Research has shown that CORT108297 is under study for its potential to improve memory and thinking in individuals at risk for Alzheimer's. Current studies are assessing the drug's safety in humans. As this trial is in an early stage, researchers continue to gather data on how well participants tolerate CORT108297.
Early results have not indicated any serious side effects, but more detailed safety information is still required. As a new drug, its side effects are monitored closely. Participants will have regular check-ins to ensure their safety throughout the trial.12345Why do researchers think this study treatment might be promising for Alzheimer's?
Most treatments for Alzheimer's disease focus on managing symptoms with medications like cholinesterase inhibitors and memantine. However, CORT108297 is unique because it targets the stress hormone cortisol, which is thought to play a role in the progression of Alzheimer's. This new approach could slow down the cognitive decline by reducing the harmful effects of cortisol on the brain. Researchers are excited because this mechanism offers a fresh angle in tackling the disease, potentially providing benefits beyond what current treatments can achieve.
What evidence suggests that CORT108297 might be an effective treatment for Alzheimer's disease?
Research has shown that CORT108297, a drug that blocks certain stress hormones, may improve memory and thinking in individuals with mild memory problems due to Alzheimer's disease. This trial will evaluate CORT108297 in individuals with mild cognitive impairment and those who are cognitively normal but at risk for Alzheimer's. Studies suggest that stress hormones can affect the brain in Alzheimer's, and CORT108297 targets these stress-related pathways to potentially enhance brain function. Previous research indicated that managing stress hormones might slow the decline in memory and thinking seen in Alzheimer's. While more information is needed, these findings suggest that CORT108297 could be a promising option for those at risk of or experiencing early signs of Alzheimer's.13467
Who Is on the Research Team?
Cynthia A Munro, PhD
Principal Investigator
Johns Hopkins School of Medicine
Are You a Good Fit for This Trial?
This trial is for adults with mild cognitive impairment due to Alzheimer's or at risk for it because of family history, genetics, or memory concerns. Participants must be non-smokers in good health, not on certain medications, and have a study partner available. They cannot join if they have other significant illnesses, are taking conflicting drugs like CYP3A inhibitors (including grapefruit juice), or have had recent surgery.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CORT108297 and placebo in a 2-week, randomized, placebo-controlled crossover study
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- CORT108297
- Placebo
Trial Overview
CORT-X is testing CORT108297 against a placebo to see if it can improve memory and executive function after stress in people with mild cognitive impairment from Alzheimer's or those at risk. It's a two-week treatment within a 10-week trial involving six visits where everyone gets both the drug and placebo at different times.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Individuals with mild cognitive impairment due to Alzheimer's disease
Individuals who are cognitively normal but who are at risk for Alzheimer's disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
Private Philanthropic Funds
Collaborator
Private Philanthropic Funds
Collaborator
Citations
CORT108297 for People at Increased Risk for Alzheimer's
This study will test whether the drug can improve memory and thinking in people who have mild cognitive impairment (MCI) due to Alzheimer's.
New selective glucocorticoid receptor modulators reverse ...
In Alzheimer's disease (AD), cognitive deficits and psychological symptoms are associated with an early deregulation of the hypothalamic-pituitary-adrenal axis.
Central Role of Glucocorticoid Receptors in Alzheimer's ...
It appears that MDD accelerates age-related cognitive decline (Gualtieri and Johnson, 2008) and promotes the conversion of mild cognitive ...
Volunteer for Research
In this study, we are looking to evaluate the effectiveness of deep brain stimulation of the fornix to slow the cognitive decline associated with Alzheimer's.
Alzheimer's disease drug development pipeline: 2024
Mild cognitive impairment (MCI) affects approximately 22% of the over-age 65 group, and AD is the cause of MCI in approximately 50% of cases.
Therapeutic approaches for improving cognitive function in the ...
In this paper, we reviewed the recent evidence of pharmacological and non-pharmacological interventions aimed at improving or maintaining cognition in the ...
7.
centerwatch.com
centerwatch.com/clinical-trials/listings/NCT04601038/trial-of-cort108297-to-attenuate-the-effects-of-acute-stress-in-the-allocortex-cort-xTrial of CORT108297 to Attenuate the Effects of Acute ...
CORT-X will examine if mitigation of stress-mediated pathogenesis of Alzheimer's disease (AD) is a feasible target for intervention in ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.